<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00162903</url>
  </required_header>
  <id_info>
    <org_study_id>26955</org_study_id>
    <nct_id>NCT00162903</nct_id>
  </id_info>
  <brief_title>Nitric Oxide, Endothelin-1, and the Patency of Ductus Arteriosus in Preterm Infants</brief_title>
  <official_title>The Role of Nitric Oxide, Endothelin-1, and Inflammatory Mediators in the Patency of Ductus Arteriosus in Preterm Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <brief_summary>
    <textblock>
      BACKGROUND Patent ductus arteriosus (PDA) is a frequent clinical event in preterm infant. The&#xD;
      cardiopulmonary functions of these preterm babies may be adversely affected by the patency of&#xD;
      ductus arteriosus. Ductal tissues are sensitive to the constricting effect of endothelin-1&#xD;
      and the dilating effect of prostaglandins, inflammatory mediators, and concentration of&#xD;
      oxygen.&#xD;
&#xD;
      OBJECTIVE To examine the role of endogenous nitric oxide (NO) and endothelin-1 (ET-1) in the&#xD;
      pathogenesis of patent ductus arteriosus of the preterm infants. We hypothesize that the&#xD;
      patency of ductus arterious in preterm infants is probably due to inappropriate production of&#xD;
      endogenous nitric oxide and the interaction with various inflammatory mediators and&#xD;
      prostaglandins, which is different from those of term infants. In addition, the secretion of&#xD;
      endothelin is probably decreased. The purpose of this study is to monitor the changes of&#xD;
      these substance sequentially, and to evaluate the relationship among endothelin-1, endogenous&#xD;
      nitric oxide, and inflammatory mediators in the pathophysiology of patent ductus arteriosus&#xD;
      in preterm infants.&#xD;
&#xD;
      METHODS AND MATERIALS&#xD;
&#xD;
        1. Inclusion criteria:&#xD;
&#xD;
             1. Preterm infants with gestational age less than 32 weeks or birth weight less than&#xD;
                2000 gm.&#xD;
&#xD;
             2. Informed consent&#xD;
&#xD;
        2. Numbers of study population:&#xD;
&#xD;
           With 80-100 evaluable infants (40-50 patients in PDA and non-PDA groups, respectively)&#xD;
&#xD;
        3. Blood sample, collecting on day 1,3,7 after regular echocardiographic evaluation, is&#xD;
           assessed for inflammatory mediator (IL-8, IL-10), nitric oxide metabolites (nitrite and&#xD;
           nitrate), endothelin-1, and cGMP&#xD;
&#xD;
        4. Statistical analysis: Student t-test testing the differences of clinical data, Wilcoxon&#xD;
           signed rank test for comparing data obtained between the PDA and non-PDA patients, the&#xD;
           PDA patients before and after intravenous indomethacin, and those who are responsive or&#xD;
           refractory to the therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2002</start_date>
  <completion_date>December 2002</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Defined Population</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <enrollment>80</enrollment>
  <condition>Patent Ductus Arteriosus</condition>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of the patency of ductus arteriosus&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Congenital anomalies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Year</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wu Shiun Hsieh, M.D</last_name>
    <role>Study Director</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <verification_date>October 2001</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2005</study_first_posted>
  <last_update_submitted>November 22, 2005</last_update_submitted>
  <last_update_submitted_qc>November 22, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2005</last_update_posted>
  <keyword>Preterm infant, Patent ductus arteriosus, Nitric oxide,Endothelin-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ductus Arteriosus, Patent</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

